Eli Lilly Shares Gain After Drug-Maker Gets FDA's Nod For Early Alzheimer's Treatment

  • 2 months ago
In a significant development in the battle against Alzheimer’s disease, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Alzheimer’s treatment, “Kisunla.”

Category

🗞
News
Transcript
00:00🎵

Recommended

0:39
I
Up next
Two Top Executives Resign as Investigation Links Deaths to Kobayashi Pharmaceutical's Rice Products
Benzinga
1:04
Jim Cramer Sees Eli Lilly As More Than A 'One-Trick Pony' After FDA Advisors Back Its Alzheimer's Drug: 'It's Ultimately Headed To A Trillion Dollar Valuation'
Benzinga
1:30
FDA approves new Alzheimer’s drug from Eli Lilly
The Street
0:58
Pfizer Settles Zantac Lawsuits, Agrees To $250M Settlement To Reduce Liability: Report
Benzinga
1:31
Why Is The Fed Still So Aggressive? - Jeremy Schwartz, Chief Investment Officer at WisdomTree
Benzinga
1:02
Jamie Dimon Likens AI To The 'Printing Press,' Says It Will Be A 'Huge Aid' To Recognize Patterns Of Success: 'Anything We Offer...Will Be Driven A Lot By AI'
Benzinga
1:45
Are Housing Stocks Pointing Towards A Recession? - $TOL
Benzinga
1:59
Are we in an earnings recession? - Marc Chaikin, Founder of Chaikin Analytics
Benzinga
0:37
Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows
Benzinga
3:04
How End Of Month Buy And Sell Imbalances Effected Stock Movements
Benzinga
0:40
Jeff Bezos' Original Book Business At Amazon Garnered $16.9B In 10 Months, With More Than Half Of It From US Alone: Report
Benzinga
0:39
Asana Announces $150 Million Stock Buyback: What To Know
Benzinga
1:09
Ozempic Maker's Parent Company To Invest $7B Annually By 2030: 'We Have More Money Than Ever To Invest'
Benzinga
1:24
What's the word from C-suites about AI risks and benefits - $AMZN $GOOG $MSFT $AI
Benzinga
3:35
“Personally I Think AI Is Overhyped And We’re Going To Run Into Some Real Issues”
Benzinga
1:40
Is Managing Volatility Really An Asset Class?
Benzinga
0:37
Medical Monitoring Provider Dexcom's Stock Drops 40% as Q2 Revenue Misses Estimates, Lowers Full-Year Guidance
Benzinga
13:34
"The Second Half Of September Is When The Trouble Tends To Come" - Ryan Detrick, CMT, Carson Group
Benzinga
7:13
From Meme to Market: Apu Apustaja's Journey to a $380M Market Cap
Benzinga
1:08
As Global Markets Roil, Strategist Soothes Nerves: 'Some Normal Action Under The Surface' As 'Tech Got Way Ahead Of Itself'
Benzinga
1:54
Where Does The Market Go From Here? “There May Be Some More Downside Ahead Of Us”
Benzinga
1:07
Jim Cramer Stands By Nvidia And Eli Lilly Despite Market Dips, Says 'Terrific Time To Take Some Profits'
Benzinga
1:03
Jim Cramer Pumps The Brakes On Alphabet Sell-Off: 'It's Just Got Too Much Going For It'
Benzinga
8:01
“It’s jaw dropping action” - The NVDA And SMCI Story
Benzinga
1:45
Atlas Lithium $ATLX Positions Itself To Meet Soaring Global Lithium Demand W/ Strategic Investments
Benzinga